Literature DB >> 24691833

[Cardiovascular pharmacotherapy. Risks and adverse effects].

N Voigt1, J Heijman, D Dobrev.   

Abstract

Adverse side effects of drugs are a significantly underestimated problem in modern medicine. In this review article, we summarize common adverse side effects of cardiovascular drugs. In particular, we highlight the factors promoting these adverse side effects in patients, including reduced hepatic or renal clearance in elderly patients that often requires dosage adjustment. Pharmacodynamic and pharmacokinetic interactions between drugs (e.g. through the cytochrome P450 system or P-glycoproteins) can modify the plasma concentration of many compounds, thereby also increasing the likelihood of unwanted side effects. The most prominent cardiac side effects include arrhythmias, e.g. atrioventricular (AV) block, drug-induced long-QT syndrome and torsade de pointes and altered inotropy. Non-cardiac side effects are subsequently discussed grouped by drug class. A better understanding of the risks and side effects of cardiovascular drugs is expected to reduce the mortality and morbidity associated with adverse side effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691833     DOI: 10.1007/s00059-014-4066-5

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  33 in total

Review 1.  Drug interactions--principles, examples and clinical consequences.

Authors:  Ingolf Cascorbi
Journal:  Dtsch Arztebl Int       Date:  2012-08-20       Impact factor: 5.594

Review 2.  [Anticoagulation].

Authors:  B Pötzsch
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-05       Impact factor: 0.840

3.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

Review 4.  From the ryanodine receptor to cardiac arrhythmias.

Authors:  D A Eisner; T Kashimura; L A Venetucci; A W Trafford
Journal:  Circ J       Date:  2009-08-10       Impact factor: 2.993

5.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 6.  Electrical storm: recent pathophysiological insights and therapeutic consequences.

Authors:  Yukiomi Tsuji; Jordi Heijman; Stanley Nattel; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2013-02-21       Impact factor: 17.165

7.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

8.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

9.  Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation.

Authors:  Niels Voigt; Jordi Heijman; Qiongling Wang; David Y Chiang; Na Li; Matthias Karck; Xander H T Wehrens; Stanley Nattel; Dobromir Dobrev
Journal:  Circulation       Date:  2013-11-18       Impact factor: 29.690

10.  Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation.

Authors:  Jordi Heijman; Gerd Heusch; Dobromir Dobrev
Journal:  Clin Med Insights Cardiol       Date:  2013-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.